The Feasibility of Half-Dose Contrast-Enhanced Scanning of Brain Tumours at 5.0 T: a preliminary study
Preprint
- 27 July 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Purpose This study investigated the Gd-based enhanced effects on brain tumours with half-dose at 5.0 T and with full-dose at 3.0 T. Both quantitative and subjective evaluation parameters suggested that half-dose enhanced scanning at 5.0 T MRI might be feasible to meet the clinical diagnostic requirements. Methods Twelve subjects diagnosed with brain tumours were included in this study, and scanned after contrast agent injection at 3.0 T (full-dose) and 5.0 T (half-dose) with a 3D T1-weighted gradient echo sequence, respectively. The post-contrast images were compared between 5.0 T and 3.0 T, in terms of the signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR) and subjective image quality score with a ten-point Likert scale. Comparing quantitative indices and subjective picture quality ratings with a paired Student's t-test and assessing inter-reader agreement with the intra-class correlation coefficient (ICC). Results A total of 16 enhanced tumours lesions were detected. The SNR was significantly higher at 5.0 T than 3.0 T in gray matter, white matter and enhanced lesions (p < 0.001). The CNR was also significantly higher at 5.0 T than 3.0 T MRI in gray matter-tumor lesion, white matter-tumor lesion, and gray matter-white matter (p < 0.001). Subjective evaluation showed that the internal structure and outline of the tumor lesions were more clearly displayed with half-does at 5.0 T, and the enhanced effects of the lesions was comparable to that with full-dose at 3.0 T. All subjective scores were good to excellent at both 5.0 T and 3.0 T. Conclusion 5.0 T half-dose intravenous contrast agents enhanced scanning might be feasible to meet the clinical diagnostic requirements of brain tumours.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Effect of r1 and r2 relaxivity of gadolinium‐based contrast agents on the T1‐weighted MR signal at increasing magnetic field strengthsContrast Media & Molecular Imaging, 2013
- Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded readEuropean Radiology, 2013
- Magnetic Resonance Imaging (MRI) Contrast Agents for Tumor DiagnosisJournal of Healthcare Engineering, 2013
- Gadolinium‐based contrast agents for magnetic resonance cancer imagingWIREs Nanomedicine and Nanobiotechnology, 2012
- Whole‐body imaging at 7T: Preliminary resultsMagnetic Resonance in Medicine, 2008
- Gray matter-white matter contrast on spin-echo T1-weighted images at 3 T and 1.5 T: a quantitative comparison studyEuropean Radiology, 2007
- Detection of brain metastasis at 3T: comparison among SE, IR-FSE and 3D-GRE sequencesEuropean Radiology, 2007
- The optimal use of contrast agents at high field MRIEuropean Radiology, 2006
- Brain Tumors: Full- and Half-Dose Contrast-enhanced MR Imaging at 3.0 T Compared with 1.5 T—Initial ExperienceRadiology, 2005
- Signal‐to‐noise ratio and absorbed power as functions of main magnetic field strength, and definition of “90°” RF pulse for the head in the birdcage coilMagnetic Resonance in Medicine, 2001